Michel Fabbro
Overview
Explore the profile of Michel Fabbro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
3022
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Ferron G, de Rauglaudre G, Becourt S, Delanoy N, Joly F, Lortholary A, et al.
Gynecol Oncol
. 2023 Jan;
170:186-194.
PMID: 36706645
Aim: The oral anti-angiogenic therapy nintedanib prolongs progression-free survival (PFS) when combined with chemotherapy after primary surgery for advanced epithelial ovarian cancer. The randomized phase II CHIVA trial evaluated the...
22.
Bourien H, Bengrine Lefevre L, Mouret-Reynier M, Asselain B, Lucas B, Gavoille C, et al.
Anticancer Res
. 2023 Jan;
43(2):653-662.
PMID: 36697069
Background/aim: Olaparib was approved in 2014 by the European Medicines Agency (EMA) as maintenance treatment for patients with breast cancer gene (BRCA)-mutated platinum-sensitive relapsed high-grade epithelial ovarian cancer (EOC) following...
23.
Colomba E, Alexandre J, Le Teuff G, Genestie C, Coupez D, Coquard I, et al.
Gynecol Oncol
. 2022 Dec;
169:78-84.
PMID: 36521352
Background: Around 15% of metastatic endometrial carcinoma (EC) are MMRd/MSI-H improving response to immune checkpoint inhibitors (ICI). So far, few data existed considering the chemotherapy (CT) sensitivity in MMRd/MSI-H EC,...
24.
Mourksi N, Dalban C, Colombe-Vermorel A, Odeyer L, Simioni V, Frenel J, et al.
Mol Oncol
. 2022 Nov;
17(1):27-36.
PMID: 36370117
Resistance of advanced hormone-dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor)...
25.
Fabbro M, Jacot W, Jarlier M, Guiu S, DHondt V, Pouderoux S, et al.
Cancer Rep (Hoboken)
. 2022 Oct;
6(1):e1732.
PMID: 36302744
Background: Acceptability and tolerance of chemotherapy on patients treated for breast cancer remain challenging. Complementary approaches such as hypnosis may have a favorable impact both at the time of announcing...
26.
Selle F, Boffa J, Etienne G, Angelergues A, Augereau P, Berton D, et al.
Bull Cancer
. 2022 Sep;
109(12):1245-1261.
PMID: 36109248
Objective: Despite an increasing number of therapeutic indications, there are no specific recommendations regarding the management of PARP inhibitors other than what is specified in the SmPC of each substance....
27.
Joly F, Fabbro M, Berton D, Lequesne J, Anota A, Puszkiel A, et al.
Gynecol Oncol
. 2022 Jul;
166(3):389-396.
PMID: 35902297
Background: Anti-angiogenic rechallenge with bevacizumab plus chemotherapy is effective in recurrent ovarian cancer (rOC); however, data are limited on tyrosine kinase inhibitors after progression on maintenance bevacizumab. Methods: In the...
28.
Lesueur P, Damaj G, Hoang-Xuan K, Roland V, Schmitt A, Chinot O, et al.
Blood Adv
. 2022 Jun;
6(16):4807-4815.
PMID: 35772168
The optimal consolidation strategy for primary central nervous system lymphoma (PCNSL) remains controversial. Preventing radio-induced neurotoxicity of consolidation treatment through reduced-dose whole-brain radiotherapy (rdWBRT) at a dose of 23.4 Gy...
29.
Neron M, Guille A, Allegre L, Colombo P, Leaha C, Adelaide J, et al.
J Pers Med
. 2022 May;
12(5).
PMID: 35629078
Hormone therapy (HT) is an effective treatment for metastatic endometrial carcinoma (mEC), with limited toxicity and low cost. We focused on molecular analysis of mECs treated by HT and, for...
30.
Bonsang-Kitzis H, Panchbhaya N, Bats A, Pujade-Lauraine E, Pautier P, Ngo C, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565475
The surgical specificities of advanced low-grade serous ovarian carcinoma (LGSOC) have been little investigated. Our objective was to describe surgical procedures/complications in primary (PDS) compared to interval debulking surgery (neoadjuvant...